Melanotan-1: Side Effects

Safety Notice#

The safety profile of Melanotan-1 in humans has not been established through controlled clinical trials. The information below is derived primarily from animal studies and should be interpreted accordingly.

Documented Adverse Effects#

We synthesized nonclinical and clinical safety evidence for Melanotan‑1 (afamelanotide; NDP‑α‑MSH) focusing on adverse effects, their frequency and severity, and exposure context. A structured summary is provided below, with a tabular synopsis embedded.

Animal (nonclinical) data

• Models, dosing, and findings: Available excerpts report short‑term pigmentation models in mice with subcutaneous NDP‑α‑MSH and rodent radiolabel distribution after s.c. dosing. These show robust eumelanin induction and high early distribution to kidney/urine, liver, and small intestine, consistent with renal elimination. Formal GLP toxicology summaries (species, NOAEL/MTD, safety pharmacology for cardiovascular, hepatic, renal, endocrine, reproductive, and histopathology) were not retrieved in the accessible texts. No afamelanotide‑specific tumorigenicity signal was identified in the provided preclinical summaries; melanoma development in cited mouse work relates to UV/genetic models rather than afamelanotide exposure (qualitative only). Thus, documented animal adverse effects in the retrieved evidence are limited to pigmentation changes and tissue distribution profiles; quantitative toxicities and organ pathology were not reported in the excerpts.

Human data (clinical trials, cohorts, and long‑term exposure)

• Dosing/exposure context: In Phase 3 RCTs for erythropoietic protoporphyria (EPP), afamelanotide was given as a 16 mg subcutaneous controlled‑release implant every ~60 days (EU study, five‑implant regimen; US study, three‑implant regimen).
• Overall tolerability: Across trials, adverse events (AEs) were mostly mild to moderate; serious adverse events (SAEs) were judged unrelated to study drug, and no deaths were attributed to afamelanotide.
• Common AEs with frequencies (RCTs): Nausea 18–19% (vs 17–18% placebo); implant‑site discoloration 11–19% (vs 0% placebo); nasopharyngitis 12–22% (similar to placebo); influenza 4–16% (variable, sometimes lower than placebo); fatigue 3–6% (vs 0–6%); abdominal pain 2–11% (vs 3–7%). These events were predominantly mild and transient.
• Additional common AEs (cohorts/clinical practice): Headache, fatigue, nausea, flushing, back pain, and nasopharyngitis are frequently reported; in an EMA‑directed clinical‑practice cohort, ~89% of patients experienced at least one AE, typically self‑limiting with a duration of 1–2 days and occurring within hours to one day after implantation. Long‑term cohorts (e.g., 115 patients, ~314 patient‑years) recorded high AE counts dominated by these mild events.
• Pigmentary changes: Implant‑site hyperpigmentation is common (about one‑third in some reports), and darkening of pre‑existing nevi has been observed. In Phase 3 trials, new melanocytic nevi occurred in 2/86 afamelanotide‑treated vs 1/81 placebo‑treated patients; observational cohorts over up to 8 years similarly reported isolated new nevi. Across clinical experience (reports indicating >1000 patients exposed), no melanoma events have been reported to date in the retrieved summaries.
• Hepatic effects: The NEJM trial authors reported “no evidence that afamelanotide impeded bile flow or other hepatic functions.” Observational EPP cohorts even described improvements in liver‑related laboratory parameters during treatment, suggestive of a potential protective effect in this disease context, though these were not controlled efficacy endpoints.
• Endocrine and cardiovascular safety: The retrieved clinical trial excerpts did not describe consistent endocrine abnormalities or hemodynamic (blood‑pressure/heart‑rate) signals attributable to afamelanotide. Early dose‑finding in volunteers noted that 0.16 mg/kg produced no toxicities above WHO grade 2, and higher peak exposures with aqueous formulations were associated with more frequent mild AEs such as nausea/headache, whereas the implant formulation avoids high peaks.
• Serious adverse events and malignancy: SAEs in trials were not considered drug‑related. No melanomas have been reported in the compiled clinical experience to date; small numbers of new or darkened nevi have been observed, consistent with the drug’s pigmentary mechanism.

Interpretation

• Animal studies in accessible sources corroborate pharmacologic effects (pigmentation) and renal elimination but do not provide quantitative GLP toxicology outcomes; no organ‑specific toxicities or mortality signals were retrievable from these excerpts.
• Human data consistently indicate a favorable safety profile dominated by mild, transient AEs (nausea, headache, fatigue, flushing, nasopharyngitis, back pain) and local pigmentary changes. Numerical frequencies from Phase 3 RCTs show similar rates to placebo for several systemic AEs, with implant‑site discoloration more frequent on active drug, and no hepatic, endocrine, cardiovascular, or malignancy signals detected in the retrieved reports.

Limitations

• We did not retrieve formal GLP animal toxicology reports specifying NOAEL/MTD, reproductive/endocrine or cardiovascular safety pharmacology, or histopathology; conclusions on animal adverse effects are therefore limited to qualitative observations from reviews. Several clinical cohorts summarized AEs but did not provide comprehensive denominator‑based frequencies for all event types beyond those quoted from RCTs.

Contraindications#

Known/explicit contraindications and key cautions

• Contraindications reported in an authoritative clinical pharmacology review summarizing regulatory practice: severe hepatic disease/impairment, renal impairment, pregnancy, and use in patients under 18 years of age.
• Evidence gaps noted in earlier reviews: limited pharmacokinetics, lack of data in hepatic/renal impairment, pregnancy and lactation, and other special populations. A separate survey of peptide labels indicates “no information provided” for pregnancy, lactation, and immunogenicity for SCENESSE, underscoring label data gaps.
• Trial exclusion criteria included pregnancy and hepatic dysfunction, supporting caution in these populations; patients with a history of skin cancer were excluded in some trials; twice‑yearly dermatologic examinations are recommended due to potential darkening of nevi/ephelides (carlsonUnknownyearfamelanotideforerythropoietica pages 1-2, carlsonUnknownyearfamelanotideforerythropoietic pages 1-2).

Drug–drug interaction data (clinical or label-derived)

• No formal pharmacokinetic drug–drug interaction (DDI) studies or specific CYP/transporter interaction statements were identified in the available literature extracts. Afamelanotide is a peptide analogue released from a biodegradable implant, with plasma concentrations falling below quantitation by ~10 days post‑implant and an apparent plasma t1/2 ~30–50 minutes, while clinical effects persist for weeks due to melanogenic biology. These features and the absence of metabolism data in reviews suggest low likelihood of classic CYP‑mediated DDIs but do not rule out pharmacodynamic interactions.

Mechanism‑based and theoretical interactions Given afamelanotide’s MC1R agonism and broader melanocortin biology, the following potential interactions warrant consideration:

• Phototherapy/UV exposure: MC1R activation increases eumelanin, enhances nucleotide excision repair, and reduces UV‑induced DNA damage; afamelanotide increases melanin density and may change skin response to phototherapy or artificial irradiation protocols. Monitoring sun/UV exposure patterns and avoiding reliance on artificial irradiation tests is recommended in clinical assessments; prior narrow‑band UVB phototherapy raised DNA‑damage concerns, so concomitant phototherapy should be used cautiously with dermatologic monitoring.
• Pigmented lesion surveillance: Drug‑induced tanning and local hyperpigmentation can darken pre‑existing nevi and rarely coincide with new nevi; periodic full‑body skin examinations (e.g., twice yearly) are advised to avoid misattribution and to detect pathology early.
• Immune and anti‑inflammatory pathways: MC1R signaling exerts anti‑inflammatory effects in multiple cell types and models. While no clinical DDI studies exist, concomitant use with systemic immunomodulators could theoretically yield additive immunomodulatory effects; clinical vigilance for infection or altered inflammatory responses is reasonable, especially in immunocompromised states.
• Endocrine/HPA axis considerations: Melanocortins (e.g., ACTH) regulate the HPA axis via MC2R; α‑MSH analogues like afamelanotide are designed to target MC1R, but melanocortin pathways intersect with endocrine stress responses. Although clinical endocrine DDIs were not identified, theoretical interactions with drugs affecting steroidogenesis or HPA axis regulation warrant awareness.
• Cardiometabolic considerations: MC1R activation has been linked to anti‑inflammatory and metabolic effects (e.g., macrophage cholesterol efflux in preclinical models). No cardiovascular hemodynamic interaction signals were identified for afamelanotide; however, cross‑talk with cAMP/ERK/Akt pathways suggests caution in patients receiving agents that broadly modulate these cascades, recognizing that clinical evidence is lacking.

Special populations and administration considerations

• Hepatic/renal impairment: Contraindicated in severe hepatic disease/impairment and in renal impairment per the clinical pharmacology review; PK and safety data are limited in these populations.
• Pregnancy and lactation: Contraindicated in pregnancy per the clinical pharmacology review; pregnancy increases endogenous α‑MSH and pigmentation, reinforcing a conservative approach. Label‑level information on lactation was not available in surveyed summaries; avoid use pending definitive data.
• Age: Not for use in patients under 18 years.
• Dermatologic monitoring: Because afamelanotide alters pigmentation and may darken nevi, schedule periodic skin examinations during therapy.

Conclusions

• Known/explicit contraindications: severe hepatic disease/impairment, renal impairment, pregnancy, and age <18 years.
• Known interactions: No specific clinical DDIs identified; limited metabolism/PK information and peptide nature suggest low CYP‑mediated DDI potential, but definitive studies are lacking.
• Mechanism‑based theoretical interactions: altered responses to UV/phototherapy; need for heightened dermatologic surveillance; potential additive immunomodulation with immunosuppressants; theoretical endocrine/HPA axis cross‑talk; and pathway cross‑talk with drugs affecting cAMP/ERK/Akt signaling, all without direct clinical DDI evidence.

Toxicology#

Acute toxicity (LD50) • No LD50 values were located in the retrieved literature excerpts. The expert review did not report acute lethal dose data; such values, if generated, are typically contained in regulatory nonclinical dossiers not available in our retrieved set.

Organ toxicity and target‑organ findings • Human tolerability: Across clinical experience summarized in a peer‑reviewed review, afamelanotide was generally well tolerated; common short‑term adverse reactions include nausea, fatigue, flushing, and headache. In one dose‑finding study using subcutaneous injections, 0.16 mg/kg produced tanning without toxicities above WHO grade 2. • Liver laboratory signals: Two observational cohorts in erythropoietic protoporphyria (EPP) report improvement in liver function tests during afamelanotide treatment, consistent with a potential hepatoprotective effect; one cohort with long follow‑up reported no emergent organ‑toxicity signal on routine labs. These are observational findings and should be interpreted cautiously. • Distribution to kidney/liver in rodents: Animal distribution studies found high levels in kidney/urine and measurable levels in small intestine and liver 1–4 h after subcutaneous dosing, consistent with predominant renal excretion; organ pathology results were not reported in the retrieved excerpts.

Mutagenicity/genotoxicity testing • No primary genotoxicity results (Ames, in vitro chromosomal aberration/mouse lymphoma, in vivo micronucleus/Comet) were identified in the retrieved sources. Standard ICH S2 testing would usually be summarized in regulatory assessment reports, which were not available in our evidence set.

Dose–response relationships • Pharmacodynamic effect: Pigmentation increases are dose‑related. In early clinical dosing, 0.16 mg/kg injections produced maximal tanning relative to higher doses tested (0.26–0.4 mg/kg). Implant doses between 5–40 mg produced dose‑related pigmentation, with strongest effects at 20–40 mg; the marketed implant is 16 mg every ~60 days. • Liver‑related labs: In an observational study of 70 EPP patients, cumulative afamelanotide dosing was associated with dose‑dependent reductions in PPIX and improvements in ALAT and bilirubin, with clearer effects when patients received >8 implants over two years; PPIX also rose with time since last implant, suggesting an immediate dose–response component. Given study design and journal quality, these findings warrant cautious interpretation.

Overall assessment • Within the accessible, peer‑reviewed summaries, afamelanotide shows a favorable clinical tolerability profile and clear dose‑dependent pharmacodynamic effects on pigmentation. However, we did not retrieve formal LD50 values, GLP repeat‑dose organ‑toxicity results, or definitive genotoxicity outcomes for afamelanotide; these are typically detailed in regulatory documents (e.g., EPAR/NDA pharmacology‑toxicology reviews) that were not captured here. Observational EPP cohorts suggest potential liver‑protective, dose‑dependent effects on laboratory parameters, but controlled nonclinical and clinical toxicology datasets were not available in our gathered texts.

Evidence Gaps#

• Human adverse event data is limited to anecdotal reports
• Systematic adverse event monitoring has not been conducted
• Drug interaction studies are incomplete
• Long-term safety profiles are unknown

Related Reading#

• Melanotan-1 overview and research guide
• Melanotan-1 dosing protocols
• Melanotan-1 risks and legal status